Despite the Hype, India Is Not the New China... Yet
NYT: Correct on Snowden in 2014, and Correct Today
What Will Gold Do Under a Trump Presidency?
The Trump Trade: Important to Know Where We are Today
How to Build a Business... That's Built to Last
Daniel Teper of Immune Pharmaceuticals explains the potential of bertilimumab, his company's leading product candidate.
You have to be logged in to leave a comment.
I'm sorry, but in order to complete what you're trying to do, you must be logged in.
© 2017 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).